Feb 26 (Reuters) - Eli Lilly's experimental weight-loss pill, orforglipron, caused more side effects and treatment ...

A clinical trial for diabetes that pit orforglipron, a diabetes and weight-loss pill developed by Eli Lilly, against oral ...

Eli Lilly and Company has reported detailed findings from the ACHIEVE-3 Phase III trial comparing the efficacy and safety of ...

Eli Lilly released new data on its oral pill, orforglipron, Thursday, showing it's almost as good as Ozempic. The pill may be available this spring.

Orforglipron, which could be approved for obesity next quarter, proved superior at cutting blood sugar and body weight — but at the expense of higher side effect rates.

The stock looks unstoppable.

Eli Lilly's full-year guidance comes in stark contrast to the outlook of Novo Nordisk, which warned it sees sales and profit ...

Eli Lilly isn't a one-trick pony.

Indiana Attorney General Todd Rokita has filed a lawsuit against Eli Lilly, alleging the company contributed to inflated insulin prices over the past decade. The state is seeking injunctive relief, ...

Eli Lilly and Company (NYSE:LLY) is included in the list of the best performing S&P 500 stocks in the last five years. As of February 6, 2026, robust demand for the company’s obesity and diabetes ...